A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
- 14 January 2010
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 115 (2) , 315-325
Abstract
In chronic-phase chronic myeloid leukemia (CML) patients, the lack of a major cytogenetic response (< 36% Ph+ metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy. To identify biomarkers predictive of imatinib failure, we performed gene expression array profiling of CD34+ cells from 2 independent cohorts of imatinib-naive chronic-phase CML patients. The learning set consisted of retrospectively selected patients with a complete cytogenetic response or more than 65% Ph+ metaphases within 12 months of imatinib therapy. Based on analysis of variance P less than .1 and fold difference 1.5 or more, we identified 885 probe sets with differential expression between responders and nonresponders, from which we extracted a 75-probe set minimal signature (classifier) that separated the 2 groups. On application to a prospectively accrued validation set, the classifier correctly predicted 88% of responders and 83% of nonresponders. Bioinformatics analysis and comparison with published studies revealed overlap of classifier genes with CML progression signatures and implicated β-catenin in their regulation, suggesting that chronic-phase CML patients destined to fail imatinib have more advanced disease than evident by morphologic criteria. Our classifier may allow directing more aggressive therapy upfront to the patients most likely to benefit while sparing good-risk patients from unnecessary toxicity.Keywords
This publication has 42 references indexed in Scilit:
- Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cellsMolecular Cancer Therapeutics, 2008
- Serial analysis of chromatin occupancy identifies β-catenin target genes in colorectal carcinoma cellsProceedings of the National Academy of Sciences, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approachLeukemia, 2006
- A COMBINED APPROACH TO DRUG METABOLISM AND TOXICITY ASSESSMENTDrug Metabolism and Disposition, 2006
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- Exploration, normalization, and summaries of high density oligonucleotide array probe level dataBiostatistics, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Prediction of Sensitivity to STI571 among Chronic Myeloid Leukemia Patients by Genome‐wide cDNA Microarray AnalysisJapanese Journal of Cancer Research, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002